biotech · Advanced Solid Tumor · Sjogren's Disease · CGEM
Cullinan Therapeutics
Octagon Therapeutics is a biotech organization headquartered in Providence, USA. It trades on NYSE under ticker CGEM. Primary therapeutic focus areas include Advanced Solid Tumor, Sjogren's Disease, Acute Myeloid Leukemi
Dyer St, Providence, Rhode Island 02903, US HQ
2017 Founded
7 Employees
Public company Type
CGEM · NYSE Ticker
Company details
- Status
- Public
- HQ
- Dyer St, Providence, Rhode Island 02903, US
- Founded
- 2017
- Employees
- 7
- Programs
- 16
- Drugs
- 14
- Patents
- 3
CLN-049
Phase 1 · small molecule · Relapsed/Refractory Acute Myeloid Leukemia (AML)
CLN-049 for Relapsed/Refractory Acute Myeloid Leukemia (AML) is a Phase 1 program (small_molecule) at Cullinan Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code CLN-049-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Cullinan Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Status
- active
- Trials
- 1